Risk factor
Negligible price volatility
Profitability factor
Good growth
About
Otsuka Holdings Co., Ltd. is a global enterprise with operations spanning pharmaceuticals, nutraceuticals, consumer products, and various other sectors. Its pharmaceutical division is dedicated to developing treatments for a wide array of conditions, including oncology, cardiovascular, renal, and digestive system disorders, as well as ophthalmic issues. This focus also extends to diagnostic solutions, intravenous preparations, and medical devices. The company's significant product offerings include EQUELLE, tailored for women's health and beauty; BODYMAINTÉ Jelly and Drink, formulated as conditioning food and liquid; the popular hydration beverage POCARI SWEAT; Calorie Mate, a nutritional supplement; OS-1, an oral rehydration solution; HINEX-R, a concentrated liquid diet; and Oronine H Ointment, a common household antiseptic. Beyond these, Otsuka's diverse offerings encompass soft drinks, various food products, and wines. The company is involved in the production of chemicals, including pharmaceutical intermediates, industrial chemicals, hydrazine, and specialized materials such as potassium titanate, polyolefin foams, and functional films, alongside stable isotopes. It provides clinical testing apparatus, medical equipment, analysis and measurement tools, and vehicle headlight testers. Furthermore, Otsuka's portfolio extends to cosmetics, warehousing and transport services, and advanced software for optimizing mental healthcare systems. Other products include synthetic resin molded items, paper goods, artificial turf, and a full spectrum of ceramic products—boards, walls, reliefs, terracotta, OT ceramics, portraits, and sign boards. Additionally, it offers spring and mineral water, insecticide and toiletry products, and adhesive tapes. Rounding out its operations, the company also manages a hotel. Established in 1921, Otsuka Holdings Co., Ltd. is headquartered in Tokyo, Japan.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value
Target Price
The average target price of 4578.T is 13166 and suggests 29% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc